Rubenstein E - Search Results

1

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F. Velasquez WS, et al. Among authors: rubenstein e. J Clin Oncol. 1994 Jun;12(6):1169-76. doi: 10.1200/JCO.1994.12.6.1169. J Clin Oncol. 1994. PMID: 8201379 Clinical Trial.

2

Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia.

Elting LS, Rubenstein EB, Martin CG, Kurtin D, Rodriguez S, Laiho E, Kanesan K, Cantor SB, Benjamin RS. Elting LS, et al. Among authors: rubenstein eb. J Clin Oncol. 2001 Feb 15;19(4):1137-46. doi: 10.1200/JCO.2001.19.4.1137. J Clin Oncol. 2001. PMID: 11181679

3

Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care.

Elting LS, Rubenstein EB, Rolston K, Cantor SB, Martin CG, Kurtin D, Rodriguez S, Lam T, Kanesan K, Bodey G. Elting LS, et al. Among authors: rubenstein eb. J Clin Oncol. 2000 Nov 1;18(21):3699-706. doi: 10.1200/JCO.2000.18.21.3699. J Clin Oncol. 2000. PMID: 11054443

4

Vascular access by physician assistants: evaluation of an implantable peripheral port system in cancer patients.

Rubenstein EB, Fender A, Rolston KV, Elting LS, Prasco P, Palmer J, Road I, Pollock RE, Frisbee-Hume S, Laurence D, et al. Rubenstein EB, et al. J Clin Oncol. 1995 Jun;13(6):1513-9. doi: 10.1200/JCO.1995.13.6.1513. J Clin Oncol. 1995. PMID: 7751900 Clinical Trial.

5

Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials.

Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Elting LS, et al. Among authors: rubenstein eb. Clin Infect Dis. 1997 Aug;25(2):247-59. doi: 10.1086/514550. Clin Infect Dis. 1997. PMID: 9332520

6

Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group.

Rubenstein EB, Gralla RJ, Hainsworth JD, Hesketh PJ, Grote TH, Modiano MR, Khojasteh A, Kalman LA, Benedict CR, Hahne WF. Rubenstein EB, et al. Cancer. 1997 Mar 15;79(6):1216-24. Cancer. 1997. PMID: 9070501 Clinical Trial.

7

Costs of blood transfusion: a process-flow analysis.

Cantor SB, Hudson DV Jr, Lichtiger B, Rubenstein EB. Cantor SB, et al. Among authors: rubenstein eb. J Clin Oncol. 1998 Jul;16(7):2364-70. doi: 10.1200/JCO.1998.16.7.2364. J Clin Oncol. 1998. PMID: 9667252

8

Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?

Sun CC, Bodurka DC, Donato ML, Rubenstein EB, Borden CL, Basen-Engquist K, Munsell MF, Kavanagh JJ, Gershenson DM. Sun CC, et al. Gynecol Oncol. 2002 Oct;87(1):118-28. doi: 10.1006/gyno.2002.6807. Gynecol Oncol. 2002. PMID: 12468352

9

The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis.

Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. Elting LS, et al. Among authors: rubenstein eb. Cancer. 2003 Oct 1;98(7):1531-9. doi: 10.1002/cncr.11671. Cancer. 2003. PMID: 14508842 Free article.

10

Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer.

Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, Hughes P, Moreland B, Fender A, Kennedy K, et al. Rubenstein EB, et al. Cancer. 1993 Jun 1;71(11):3640-6. doi: 10.1002/1097-0142(19930601)71:11<3640::aid-cncr2820711128>3.0.co;2-h. Cancer. 1993. PMID: 8490912 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

236 results

Search Page

Filters